When mantle cell lymphoma comes back, treatment choices have been limited.
The @FDA just approved a new treatment for MCL — on an expedited timeline, so it reaches patients sooner.
https://t.co/FXx93mRZQa
In the latest issue! Oncogenic and tumor-suppressive forces converge on a progenitor niche at the benign-to-malignant transition https://t.co/3zD38QikKK
In the latest issue! Large-scale proteomics across neurological disorders uncovers biomarker panel and targets in multiple sclerosis https://t.co/kjLaq2wNqT